QQQS - ETF AI Analysis
Top Page
Invesco NASDAQ Future Gen 200 ETF (QQQS)
Rating:54Neutral
Price Target:―
Positive Factors
Strong Recent Performance
The ETF has delivered strong gains so far this year and over the past few months, showing solid recent momentum.
High-Performing Health Care Holdings
Several top health care stocks in the portfolio have shown strong gains, helping drive the fund’s overall results.
Moderate Expense Ratio
The fund’s expense ratio is reasonably low for a specialized strategy, allowing investors to keep more of their returns.
Negative Factors
Heavy Health Care Concentration
More than half of the fund is invested in health care, which increases the risk if that sector faces a downturn.
Limited Geographic Diversification
The ETF is almost entirely invested in U.S. companies, offering little protection if the U.S. market struggles.
Small Fund Size
The relatively low assets under management may lead to higher trading costs or a greater chance the fund could be closed in the future.
QQQS vs. SPDR S&P 500 ETF (SPY)
AUM21.25M
RegionNorth America
Expense Ratio0.20%
Beta1.43
IssuerInvesco
Inception DateOct 13, 2022
Dividend Yield1.86%
Asset ClassEquity
Index TrackedNasdaq Innovators Completion Cap Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume4,367
30 Day Avg. Volume6,026
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
84.99Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering200
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
QQQS Summary
QQQS is the Invesco NASDAQ Future Gen 200 ETF, which follows the Nasdaq Innovators Completion Cap Index. It focuses on about 200 smaller, up‑and‑coming U.S. companies, especially in health care and technology. Examples of holdings include 10x Genomics and Newell Brands. Investors might consider QQQS if they want growth potential from newer, innovative businesses and broader diversification beyond the big, well-known NASDAQ names. However, because it leans heavily into smaller health care and tech stocks, its price can be more volatile and may go up and down sharply with changes in those sectors.
How much will it cost me?The expense ratio for the Invesco NASDAQ Future Gen 200 ETF (QQQS) is 0.2%, which means you’ll pay $2 per year for every $1,000 invested. This is slightly higher than the average for passively managed ETFs because it focuses on a niche group of innovative small and mid-cap companies, requiring more specialized management.
What would affect this ETF?The QQQS ETF, with its focus on innovative small and mid-cap U.S. companies, could benefit from advancements in technology and healthcare, sectors that make up a significant portion of its holdings. However, it may face challenges if interest rates rise, as smaller companies often struggle with higher borrowing costs, or if economic conditions weaken, which could impact consumer spending and industrial growth. Regulatory changes in healthcare or technology could also influence the performance of its top holdings.
QQQS Top 10 Holdings
QQQS is leaning hard into U.S. health care innovators, with names like 10x Genomics and Iovance Biotherapeutics helping drive the fund as their momentum has been rising despite choppy fundamentals. Smaller biotech and genetics plays such as Opus Genetics and Myriad Genetics are more of a headache, with weak finances and lagging trends that can tug on returns. On the tech side, MaxLinear and ChipMOS offer a steadier, semiconductor-flavored boost, while GoPro and Quantum feel more like wild cards. Overall, it’s a concentrated bet on future-facing U.S. health care and niche tech.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| QTREX Quantum Ltd | 1.05% | $229.09K | $105.98M | 33.90% | 35 Underperform | |
| Iovance Biotherapeutics | 0.97% | $212.73K | $6.60B | 583.96% | 50 Neutral | |
| Pacific Biosciences | 0.83% | $181.52K | $652.74M | 28.93% | 52 Neutral | |
| Maxlinear | 0.81% | $177.37K | $8.07B | 425.12% | 60 Neutral | |
| Pacira Pharmaceuticals | 0.76% | $167.28K | $1.45B | 59.74% | 69 Neutral | |
| GoPro | 0.74% | $161.42K | $222.70M | -42.72% | 50 Neutral | |
| ChipMOS Technologies | 0.72% | $158.49K | $2.69B | 274.49% | 64 Neutral | |
| Myriad Genetics | 0.69% | $151.88K | $401.73M | -47.69% | 41 Neutral | |
| Synaptics | 0.68% | $148.11K | $4.74B | 78.96% | 52 Neutral | |
| Heron Therapeutics | 0.67% | $147.23K | $78.90M | -70.45% | 48 Neutral |
QQQS Technical Analysis
Negative
―
Price Trends
43.43
Negative
43.13
Negative
39.88
Positive
Market Momentum
-0.82
Positive
34.62
Neutral
6.49
Positive
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For QQQS, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 42.31, equal to the 50-day MA of 43.43, and equal to the 200-day MA of 39.88, indicating a neutral trend. The MACD of -0.82 indicates Positive momentum. The RSI at 34.62 is Neutral, neither overbought nor oversold. The STOCH value of 6.49 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for QQQS.
QQQS Peer Comparison
Comparison Results
Performance Comparison
QQQS
Invesco NASDAQ Future Gen 200 ETF
40.06
6.37
18.91%
OASC
OneAscent Small Cap Core ETF
―
―
―
FSCS
First Trust Smid Capital Strength Etf
―
―
―
MYLD
Cambria Micro and SmallCap Shareholder Yield ETF
―
―
―
TMFX
Motley Fool Next Index ETF
―
―
―
BCSM
Baron SMID Cap ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents